Clopidogrel and coronary stents: risks and benefits

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Interventional Cardiology

Background:

• Clopidogrel is an oral antiplatelet medication.
• It inhibits adenosine diphosphate receptor-mediated platelet aggregation.
• Clopidogrel, combined with aspirin, treats atherothrombotic diseases.

Purpose of the Study:

• Review the role of clopidogrel in atherothrombotic diseases.
• Evaluate clopidogrel's use after coronary intervention.
• Discuss current strategies for preventing stent thrombosis.

Main Methods:

• Literature review of clopidogrel's efficacy and safety.
• Analysis of clinical trial data on clopidogrel therapy.
• Examination of mechanisms underlying stent thrombosis.

Main Results:

• Clopidogrel is essential for managing patients with coronary stents.
• Long-term clopidogrel plus aspirin therapy is indicated for preventing late stent thrombosis.
• Current therapeutic approaches focus on optimizing antiplatelet therapy.

Conclusions:

• Clopidogrel plays a significant role in managing atherothrombotic conditions and post-coronary intervention.
• Addressing late stent thrombosis necessitates prolonged clopidogrel and aspirin treatment.
• Emerging antiplatelet agents may offer improved outcomes.